Phylogeny-driven design of broadly protective sarbecovirus receptor-binding domain nanoparticle vaccines
Addetia, A.; Schaefer, A.; Sprouse, K.; Valdez, A.; Taylor, A.; Navarro, M.-J.; Brown, J. T.; Leaf, E.; Miranda, M.; Walls, A. C.; Lee, J.; Catanzaro, N. J.; Treichel, C.; Willoughby, I.; Powers, J.; Martinez, D. R.; Vesari, B.; Ravichandran, R.; Seo, A. J.; Stewart, C.; Merz, B.; Beirne, E.; Zepeda, S.; Cook, A.; Pessaint, L.; Sharma, A.; Edwards, D.; Lee, K.; Smith, K.; Starr, T. N.; Baric, R.; King, N. P.; Veesler, D.
Show abstract
Vaccines against emerging SARS-CoV-2 variants and sarbecoviruses with pandemic potential must elicit a robust humoral immune response in a population imprinted with the SARS-CoV-2 spike (S) protein. Here, we designed protein nanoparticle (NP) vaccines co-displaying the SARS-CoV-2 BA.5, SARS-CoV-1, and BtKY72 receptor-binding domains (RBDs) with or without the Wuhan-Hu-1 (Wu) RBD. We show that these vaccines elicit cross-reactive and broadly neutralizing plasma antibody responses against SARS-CoV-2 variants and sarbecoviruses in naive and pre-immune animals. Immunization with multivalent RBD-NPs overcomes immune imprinting and elicits neutralizing antibodies and memory B cells specific for the BA.5, SARS-CoV-1, and BtKY72 RBDs in mRNA-1273-vaccinated non-human primates. Multivalent RBD-NPs outperform a monovalent Wu RBD-NP vaccine by providing superior protection in mice and non-human primates challenged with the vaccine-mismatched SARS-CoV-2 XBB.1.5 or the pre-emergent RsSHC014. These data support the use of multivalent RBD-NP vaccines for SARS-CoV-2 variants and sarbecoviruses in naive and pre-immune populations.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Mosaic sarbecovirus nanoparticles elicit cross-reactive responses in pre-vaccinated animals 98%
- Single-dose respiratory mucosal delivery of next-generation viral-vectored COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2 97%
- Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection 96%
Similar papers in this journal
- A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates 97%
- Ending transmission of SARS-CoV-2: sterilizing immunity using an intranasal subunit vaccine 97%
- A broadly generalizable stabilization strategy for sarbecovirus fusion machinery vaccines 96%
Similar papers in this journal
- Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause severe disease 96%
- Permanent lymphocyte subset elimination upon a single dose of AAV-delivered depletion antibody dissects immune control of chronic viral infection 95%
- Live imaging of SARS-CoV-2 infection in mice reveals neutralizing antibodies require Fc function for optimal efficacy 95%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.